



IBA LAUNCHES A NEW COMPACT, LOW ENERGY CYCLOTRON

January 24th 2022 marked the unveiling of IBA's new compact, low energy cyclotron, the Cyclone® KEY!

The new machine will enable small and medium-sized hospitals to produce their own radiopharmaceutical products in-house, whilst providing more widespread global access to diagnostic solutions in oncology, neurology and cardiology.



Small footprint

Thanks to the Cyclone® KEY's compact size, IBA's experts have managed to minimize the footprint of the radiopharmacy to 80m².


High technology, Smooth process

Simplified design for simplified installation, operation and maintenance.

Impressive performances

Cyclone® KEY could generate up to 30 FDG doses in a 2-hour run.

Cyclone® KEY's design originates from the well-established Cyclone® KIUBE, the highest market standards in terms of radioisotopes production capacity and reliability. Discover more details with IBA expert's:



This is the Cyclone® KEY which is very small, only 1,4m high and 1,5m deep.

The Cyclone® KEY was unveiled during Arab Health 2022, an annual meeting in Dubai, UAE and presented during a VIP event in Dubai. Live or relive these moments in video!



Visit [our website](#) for more info about the Cyclone® KEY.

SUCCESS STORIES

FIRST CYCLONE® KIUBE SELF-SHIELDED ACCEPTANCE IN CHINA!



The Cyclone® KIUBE at HTA Beijing site successfully completed the acceptance test! The new radiopharmacy will now produce F-18 for in-house use as well as distribution to the nearby hospitals.

THE CYCLONE® KIUBE PASSED ITS ACCEPTANCE TEST AT SICHUAN PROVINCE CYCLOTRON MEDICAL SCIENCE CO., LTD IN CHENGDU, CHINA.

The new radiopharmacy will now be able to start its production of F-18 compounds using the Cyclone® KIUBE and the Synthera®+ platform.

At this stage, the GOSUN group owns four radiopharmaceutical production plants; Guangdong equipped with a Cyclone® 18, Hunan and Chengdu equipped with Cyclone® KIUBE and the Kunming site which also plans to

use an IBA Cyclotron. GOSUN runs a R&D center and will cooperate more closely with IBA in the development of new radiopharmaceuticals.




INSTALLATION OF THE CYCLONE® 70 AT THE INSTITUTE OF BASIC SCIENCE IN KOREA.



When a 140 tons cyclotron has to be placed into its vault, it is always impressive! It requires precision expertise and a close attention to every detail. After the rigging, the team could start the installation of the Cyclone® 70P. This is the 4th installation of such system for IBA team of experts involved. Watch the video of the rigging !

6TH CYCLONE® KIUBE RIGGING IN CHINA IN 2021!

The Cyclone® KIUBE has been placed into its final position at HIC in Changshu, China. The new radiopharmacy will produce F-18 compounds as well as other novel radioisotopes.



ACCEPTANCE OF THE CYCLONE® KIUBE AND SYNTERA®+ IN FUSHAN, CHINA

Junqi Pharmaceutical Tech Co., LTD will now be able to start their F-18 production with State of the Art equipments; the Cyclone® KIUBE and Synthera®+ synthesizer.



EU MARKETING AUTHORIZATION FOR THE DISTRIBUTION OF GA-68 PRODUCED ON IBA CYCLOTRON.

The Portuguese regulatory agency (INFARMED), has granted the first EU marketing authorization to distribute ⁶⁸Ga[⁶⁸Ga]GaCl₃ with a new process for producing Gallium-68 with an IBA cyclotron using a liquid target for human use.

This FGD-like production process is easy to implement and allows cyclotron production centers to maximize the use of their equipment. The process consists of the irradiation of an enriched ⁶⁸Zn solution in a ⁶⁸Ga liquid target installed on a Cyclone® KIUBE. The target solution is then transferred to a Synthera® extension module which purifies the irradiated solution to obtain [⁶⁸Ga]GaCl₃, which is equivalent to [⁶⁸Ga]GaCl₃ from the commercial ⁶⁸Ge/⁶⁸Ga generators.

|| We can see a clear benefit to producing ⁶⁸Ga with a cyclotron using a liquid target; the production is consistent and allows a higher production volume. This new patented process provides a viable alternative for facilities with cyclotrons securing ⁶⁸Ga access locally and for distribution. ||

Antero Abrunhosa
Director at ICNAS

IBA AND SCK CEN JOIN FORCES TO ENABLE PRODUCTION OF ACTINIUM-225

IBA and SCK CEN entered a strategic R&D partnership to enable the production of Actinium-225 (²²⁵Ac), a novel radioisotope which has significant potential in the treatment of cancer.


Nuclear medicine has evolved considerably over recent years with the emergence of radiotheranostics. One of the most promising isotopes used in radiotheranostics is the alpha-emitting Actinium-225. This is due to its useful characteristics: in its decay, it kills cancer cells, having high cytotoxic potency within a very short range. Moreover, its half-life (10 days) enables a smooth process for logistics and centralized distribution.

One of the main challenges to making this therapeutic solution accessible for the greatest number of patients is ensuring the availability of high-quality Actinium-225 in large quantities. By joining their unique expertise and resources, SCK CEN and IBA will be able to work towards the large-scale production of Actinium-225 for patient use. Concurrently, this collaboration will allow them to establish themselves as leading global partners in the production of Actinium-225.

[Read the press release](#)

IBA AND NORTHSTAR MEDICAL RADIOISOTOPES SIGN CONTRACT FOR RHODOTRON® FOR COMMERCIAL PRODUCTION OF ACTINIUM-225 (AC-225)

IBA and NorthStar Medical Radioisotopes, LLC announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.



The accelerator will be exclusively used for the production of no-carrier added (n.c.a.) Actinium-225 (²²⁵Ac), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists. NorthStar previously purchased two Rhodotron® accelerators from IBA for its newly completed molybdenum-99 [Mo-99] production facility.

[Read the press release](#)


|| Theranostics have the potential to revolutionize the way we treat cancer. By partnering with IBA, we can use our nuclear knowhow to transform isotopes meant to become radioactive waste into therapeutic compounds. Our complementary expertise will enable us to work towards providing the greatest number of patients with the benefits of this latest generation of nuclear medicine. ||



Eric van Walle, Director General of SCK CEN

CLOSER TO THE USERS

ONSITE START UP TRAINING IN CAIRO




The International Medical Center's team followed their onsite start-up training with Maxim Kashentsev. Thank to this course, the team based in Cairo, Egypt, is now ready to operate their Cyclone®18 to have an easy start of FDG production!

IBA USERS DIGITAL DAYS 2021

We were very happy to see all of you and to exchange with you about novelties as well as tips & tricks.

We hope that we will soon be able to see each other face to face.



IBA AROUND THE WORLD


At IBA, we are keen on sharing our solutions with the rest of the world. Here are some events where you might have seen us...

E-POSTER @EANM

Several users sites shared their experience with the production of Ga-68 using a cyclotron. Discover the insights from ICNAS - Institute for Nuclear Sciences Applied to Health in Portugal, Bad Deynhausen in Germany, Doctors Hospital in Mexico and the University of Chicago in the United States!

[Read it here](#)

DIAGNOSTICS SUMMIT



We were pleased to showcase IBA's integrated solutions for radiopharmaceutical productions including our cutting-edge cyclotrons and radiosynthesis modules.

TRP SUMMIT

During this congress, IBA and SCK CEN presented how they will contribute to resolving the current Actinium shortage and support the development of alpha therapy for the largest number of patients.


OGNMB

We were happy to meet you at the 35th International Austrian Winter Symposium to talk about IBA's Radiopharmaceuticals production solutions.



ARAB HEALTH

During Arab Health annual meeting 2022, IBA unveiled its new compact low energy cyclotron; the Cyclone® KEY. We were happy to share this exciting innovation and to show a real size mock-up on the booth.



WHERE CAN YOU MEET US NEXT?

Our team will be happy to welcome you at our booth at :

- **Oncology, Beam Diagnostics and Therapy**, February 18-20, Moscow, Russia
- **SNMMI Theranostics**, March 10-12, New Orleans, USA
- **DGN**, April 27-30, Leipzig, Germany
- **Meeting of Oncologists and Radiologists of Russia & CIS**, April, 27-29, Nur- Sultan, Kazakhstan
- **BELNUS**, May 6th, Liege, Belgium
- **ANZSNM**, May 13-15 Sydney, Australia
- **ISRS**, May 29- June 2, Nante, France
- **Turku PET Symposium**, June 3-6, Turku, Finland
- **SNMMI**, June 11-14, Vancouver, Canada
- **11 ICI**, June 19-23, Saskatoon, Canada
- **TWC**, June 24-26, Wiesbaden, Germany

iba-RadiopharmaSolutions.com

Sylvain Savaria
Vice President NA
Sylvain.Savaria@iba-group.com

Li Chen
Sales Director China
Chen.Li@iba-group.com

Claudia Ochoa
Vice President Western Europe & Global Chemistry Solutions
Claudia.Ochoa@iba-group.com

Peter Leitner
Vice President APAC
Peter.Leitner@iba-group.com

Ambrosio Moreno
Vice President LATAM
Ambrosio.Moreno@iba-group.com

Robert Kwizera Mugabo
Sales Area Manager EMEA
Robert.KwizeraMugabo@iba-group.com

Dmitry Cherkasov
Sales&Marketing Director Russia&CIS
Dmitry.Cherkasov@iba-group.com

Sujala Vaniyath
Chemistry Sales Manager
sujala.vaniyath@iba-group.com

IBA RadioPharma Solutions
Chemin du cyclotron, 3
1348 Louvain-la-Neuve
Belgium

Tél. : +32 10 201 275
Fax : +32 10 47 59 00
RadioPharmaSolutions@iba-group.com

RADIO PHARMA SOLUTIONS

